111 related articles for article (PubMed ID: 32165557)
1. Therapeutic and Prophylactic Antitumor Activity of an Oral Inhibitor of Fucosylation in Spontaneous Mammary Cancers.
Disis ML; Corulli LR; Gad EA; Koehnlein MR; Cecil DL; Senter PD; Gardai SJ; Okeley NM
Mol Cancer Ther; 2020 May; 19(5):1102-1109. PubMed ID: 32165557
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of fucosylation by 2-fluorofucose suppresses human liver cancer HepG2 cell proliferation and migration as well as tumor formation.
Zhou Y; Fukuda T; Hang Q; Hou S; Isaji T; Kameyama A; Gu J
Sci Rep; 2017 Sep; 7(1):11563. PubMed ID: 28912543
[TBL] [Abstract][Full Text] [Related]
3. The fucosylation inhibitor, 2-fluorofucose, inhibits vaso-occlusion, leukocyte-endothelium interactions and NF-ĸB activation in transgenic sickle mice.
Belcher JD; Chen C; Nguyen J; Abdulla F; Nguyen P; Nguyen M; Okeley NM; Benjamin DR; Senter PD; Vercellotti GM
PLoS One; 2015; 10(2):e0117772. PubMed ID: 25706118
[TBL] [Abstract][Full Text] [Related]
4. Immunization against HIF-1α Inhibits the Growth of Basal Mammary Tumors and Targets Mammary Stem Cells
Cecil DL; Slota M; O'Meara MM; Curtis BC; Gad E; Dang Y; Herendeen D; Rastetter L; Disis ML
Clin Cancer Res; 2017 Jul; 23(13):3396-3404. PubMed ID: 28039264
[No Abstract] [Full Text] [Related]
5. Comparison of two glycoengineering strategies to control the fucosylation of a monoclonal antibody.
Mishra N; Spearman M; Donald L; Perreault H; Butler M
J Biotechnol; 2020; 324S():100015. PubMed ID: 34154738
[TBL] [Abstract][Full Text] [Related]
6. Development and Preclinical Application of an Immunocompetent Transplant Model of Basal Breast Cancer with Lung, Liver and Brain Metastases.
Aprelikova O; Tomlinson CC; Hoenerhoff M; Hixon JA; Durum SK; Qiu TH; He S; Burkett S; Liu ZY; Swanson SM; Green JE
PLoS One; 2016; 11(5):e0155262. PubMed ID: 27171183
[TBL] [Abstract][Full Text] [Related]
7. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice.
Wagner S; Jasinska J; Breiteneder H; Kundi M; Pehamberger H; Scheiner O; Zielinski CC; Wiedermann U
Breast Cancer Res Treat; 2007 Nov; 106(1):29-38. PubMed ID: 17203384
[TBL] [Abstract][Full Text] [Related]
8. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
[TBL] [Abstract][Full Text] [Related]
9. Mining the pre-diagnostic antibody repertoire of TgMMTV-neu mice to identify autoantibodies useful for the early detection of human breast cancer.
Mao J; Ladd J; Gad E; Rastetter L; Johnson MM; Marzbani E; Childs JS; Lu H; Dang Y; Broussard E; Stanton SE; Hanash SM; Disis ML
J Transl Med; 2014 May; 12():121. PubMed ID: 24886063
[TBL] [Abstract][Full Text] [Related]
10. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
[TBL] [Abstract][Full Text] [Related]
11. The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFα/IL17 Dependent.
Phan-Lai V; Dang Y; Gad E; Childs J; Disis ML
Clin Cancer Res; 2016 May; 22(9):2207-16. PubMed ID: 26660518
[TBL] [Abstract][Full Text] [Related]
12. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.
Manjili MH; Wang XY; Chen X; Martin T; Repasky EA; Henderson R; Subjeck JR
J Immunol; 2003 Oct; 171(8):4054-61. PubMed ID: 14530326
[TBL] [Abstract][Full Text] [Related]
13. Cellular Fucosylation Inhibitors Based on Fluorinated Fucose-1-phosphates*.
Pijnenborg JFA; Visser EA; Noga M; Rossing E; Veizaj R; Lefeber DJ; Büll C; Boltje TJ
Chemistry; 2021 Feb; 27(12):4022-4027. PubMed ID: 33336886
[TBL] [Abstract][Full Text] [Related]
14. Use of 5-Thio-L-Fucose to modulate binding affinity of therapeutic proteins.
Zimmermann M; Nguyen M; Schultheiss CM; Kolmar H; Zimmer A
Biotechnol Bioeng; 2021 May; 118(5):1818-1831. PubMed ID: 33501689
[TBL] [Abstract][Full Text] [Related]
15. Natural history of tumor growth and immune modulation in common spontaneous murine mammary tumor models.
Gad E; Rastetter L; Slota M; Koehnlein M; Treuting PM; Dang Y; Stanton S; Disis ML
Breast Cancer Res Treat; 2014 Dec; 148(3):501-10. PubMed ID: 25395320
[TBL] [Abstract][Full Text] [Related]
16. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice.
Nanni P; Nicoletti G; De Giovanni C; Landuzzi L; Di Carlo E; Cavallo F; Pupa SM; Rossi I; Colombo MP; Ricci C; Astolfi A; Musiani P; Forni G; Lollini PL
J Exp Med; 2001 Nov; 194(9):1195-205. PubMed ID: 11696586
[TBL] [Abstract][Full Text] [Related]
17. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
18. Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma.
Astolfi A; Landuzzi L; Nicoletti G; De Giovanni C; Croci S; Palladini A; Ferrini S; Iezzi M; Musiani P; Cavallo F; Forni G; Nanni P; Lollini PL
Am J Pathol; 2005 Apr; 166(4):1205-16. PubMed ID: 15793299
[TBL] [Abstract][Full Text] [Related]
19. Effect of annatto-tocotrienols supplementation on the development of mammary tumors in HER-2/neu transgenic mice.
Pierpaoli E; Viola V; Barucca A; Orlando F; Galli F; Provinciali M
Carcinogenesis; 2013 Jun; 34(6):1352-60. PubMed ID: 23430951
[TBL] [Abstract][Full Text] [Related]
20. Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination.
Pupa SM; Invernizzi AM; Forti S; Di Carlo E; Musiani P; Nanni P; Lollini PL; Meazza R; Ferrini S; Menard S
Gene Ther; 2001 Jan; 8(1):75-9. PubMed ID: 11402305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
